1.
High-throughput screening assays for the identification of chemical probes
by Inglese, James
Nature chemical biology, 2007-08, Vol.3 (8), p.466-479
2.
Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars
by Ghasriani, Houman
Nature biotechnology, 2016-02, Vol.34 (2), p.139-141
3.
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
by Lyon, Robert P
Nature biotechnology, 2015-07, Vol.33 (7), p.733-735
4.
Strategies to Reduce the Tampering and Subsequent Abuse of Long-acting Opioids: Potential Risks and Benefits of Formulations With Physical or Pharmacologic Deterrents to Tampering
by Stanos, Steven P., DO
Mayo Clinic proceedings, 2012, Vol.87 (7), p.683-694
5.
Growing applications of "click chemistry" for bioconjugation in contemporary biomedical research
by Nwe, Kido
Cancer biotherapy & radiopharmaceuticals, 2009-06, Vol.24 (3), p.289-302
6.
Foreign protein degradation and instability in plants and plant tissue cultures
by Doran, Pauline M
Trends in biotechnology (Regular ed.), 2006, Vol.24 (9), p.426-432
7.
Toward biosimilar monoclonal antibodies
by Schneider, Christian K
Nature biotechnology, 2008-09, Vol.26 (9), p.985-990
8.
Dosage form design and development
by Allen, Loyd V., PhD, RPh
Clinical therapeutics, 2008, Vol.30 (11), p.2102-2111
9.
European perspectives on pediatric formulations
by Breitkreutz, Jörg, PhD
Clinical therapeutics, 2008, Vol.30 (11), p.2146-2154
10.
Necessity of Rethinking Oral Pediatric Formulations
by Bar-Shalom, Daniel, Mgr
Clinical therapeutics, 2014, Vol.36 (2), p.180-183
11.
WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability
by Dalvit, C
Journal of biomolecular NMR, 2001-12, Vol.21 (4), p.349-359
12.
Experimental and computational screening models for prediction of aqueous drug solubility
by BERGSTRÖM, Christel A. S
Pharmaceutical research, 2002, Vol.19 (2), p.182-188
13.
Summary of the National Institute of Child Health and Human Development–Best Pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop–Pediatric Biopharmaceutics...
by Abdel-Rahman, Susan M., PharmD
Clinical therapeutics, 2012, Vol.34 (11), p.S11-S24
14.
Extemporaneous drug formulations
by Nahata, Milap C., MS, PharmD
Clinical therapeutics, 2008, Vol.30 (11), p.2112-2119
15.
The economics of pediatric formulation development for off-patent drugs
by Milne, Christopher-Paul, JD
Clinical therapeutics, 2008, Vol.30 (11), p.2133-2145
16.
The use of ethanol in paediatric formulations in New Zealand
by Svirskis, Darren
European journal of pediatrics, 2013-02-26, Vol.172 (7), p.919-926
17.
Measurement Techniques for Respiratory Tract Deposition of Airborne Nanoparticles: A Critical Review
by Jakob Löndahl
Journal of aerosol medicine, 2014-08-01, Vol.27 (4), p.229
18.
Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles
by DYER, A. M
Pharmaceutical research, 2002, Vol.19 (7), p.998-1008
19.
What is the true solubility advantage for amorphous pharmaceuticals?
by HANCOCK, B. C
Pharmaceutical research, 2000, Vol.17 (4), p.397-404
20.
Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants
by Braun, LaToya Jones
Vaccine, 2008, Vol.27 (1), p.72-79
